Ac-SDKP vs OGP
Head-to-head comparison of Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) and OGP (Osteogenic Growth Peptide) — benefits, dosing, side effects, research data, and where to buy.
| Property | Ac-SDKP | OGP |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | N-Acetyl-Seryl-Aspartyl-Lysyl-Proline | Osteogenic Growth Peptide |
| Molecular Weight | 432.4 Da | 1600 Da |
| Half-Life | minutes | N/A |
| Amino Acids | 4 | 14 |
| Typical Dose | 10–100 µg/kg/day in pre-clinical studies | research-dependent low microgram range |
| Route | Subcutaneous | Subcutaneous/Local |
| Purity | ≥98% | ≥98% |
| Studies Count | 180 | 80 |
| Research Status | Pre-clinical | Pre-clinical |
Ac-SDKP Benefits
- ✓anti-inflammatory tissue remodeling
- ✓fibroblast modulation
- ✓microvascular protection
- ✓faster regenerative signaling
OGP Benefits
- ✓stimulates osteoblast activity
- ✓supports fracture repair
- ✓may increase bone matrix deposition
- ✓may improve healing after injury
Ac-SDKP Dosing
Research-only systemic microdoses|short daily dosing in animal models|route varies by study
OGP Dosing
research-dependent microgram or nanomolar dosing|subcutaneous or local experimental delivery|cycle-dependent in studies
Ac-SDKP Side Effects
- ⚠GI upset
- ⚠hypotension at high exposure
- ⚠unknown long-term safety
OGP Side Effects
- ⚠uncertain safety profile
- ⚠injection-site irritation
- ⚠theoretical endocrine effects
Research Overview
Ac-SDKP
Ac-SDKP has literature in tissue remodeling, angiogenesis, and organ repair models. Its strongest evidence is pre-clinical, where it modulates inflammation and fibrosis during healing.
OGP
OGP has mostly preclinical literature showing effects on bone cell signaling, mineralization, and repair models. It is not as clinically established as teriparatide or BMPs, but it is a genuine peptide in the bone-regeneration literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.